Kite Pharma's Shares Soar After Study Results

Eight patients with aggressive non-Hodgkin's lymphoma treated with Kite Pharma's cancer drug lead candidate were in complete remission and four others in partial remission, the company said Monday.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news